The results of a 12-month blind randomised trial comparing the intraocular pressure
lowering effect of timolol 0.25% with timolol 0.5% are presented. 27% of patients (22% of …

Glaucoma affects 1% of people over the age of 40 years1, 2. Patients with this diagnosis
account for about 15±25% of ophthalmic hospital outpatient visits and make up a substantial …

In the recent past glaucoma care has experienced a revolution led by new technologies and
treatments. As Knox et al describe in this issue of the BJO (p 162), new glaucoma …

Older drugs for glaucoma reduce intra-ocular pressure, but often have unpleasant adverse
effects. They still have a role in therapy, but there are now newer drugs which overcome …

As a result of our use of [beta] blockers as initial therapy for glaucoma for several decades,
we have acquired extensive knowledge about their advantages and limitations.[beta] …

Glaucoma is the most common neurodegenerative disease of the optic nerve, with a
prevalence of about 3%. 1 This means that about 150 000 Australians, about 75% of whom …

WITHIN THE LAST 20 years several new, effective, and well-tolerated glaucoma medi-
cations have been introduced. No longer is the clinician limited to pilocarpine and other …

Glaucoma is the leading cause of irreversible blindness worldwide, affecting more than 70
million people, with half unaware they are affected. 1–3 As glaucoma cannot be cured …

The safety profile of the different glaucoma medications is an important issue when initiating
therapy in glaucomatous patients. The decision on which medication to prescribe depends …

Tonometry in 9 eyes (7 patients) provides some evidence that timolol eye drops are useful in
improving control of pressure in eyes operated for closed-angle glaucoma. In cases 1 and 2 …